Celltrion Refutes Critique of CT-P13 Equivalence
Celltrion finds fault with a critique of equivalence margins used to approve its infliximab biosimilar.
The Top 5 Biosimilar Articles for the Week of August 10
Here are the top 5 biosimilar articles for the week of August 10, 2020.
Automatic Substitution Pays Off for Compass Oncology West
Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD.
Pfizer Expert Urges Employers to Get Proactive on Biosimilars
Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.
Disney Official, Others Talk About Switch to Biosimilars
Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their own hands.
Christine Simmon and the Fight for Patent Reform
Opening the door to biosimilar competition starts with breaking down the patent barrier, says Christine Simmon, JD.
At University of Missouri Health Care, Biosimilars Are Transformative but Somewhat Restricted
Pharmacy experts discuss their level of confidence with biosimilars and some of the hurdles that stand in the way of optimizing these lower-cost medicines.
Study to Evaluate Discontinuation of Biosimilar RA Treatment
Japanese investigators say more needs to be known about what happens post treatment with biosimilar infliximab in patients with rheumatoid arthritis (RA).
Polpharma Biologics: The Polish Biosimilar Powerhouse
Now that Polpharma Biologics has fully integrated Bioceros into its brand, the company hopes to become one of the world’s leading biologics manufacturers.
USP Panel Recommends Quality Upgrade for India's Biopharmaceutical Industry
United States Pharmacopeia (USP), the FDA, and others deliver constructive critique on how India can bolster quality in its biopharmaceutical industry.
Sandoz Rituximab Measures Up in DLBCL
A rituximab biosimilar in diffuse large B-cell lymphoma (DLBCL) passes the real-world test with flying colors, according to Manfred Weslau, MD.
Samsung Bioepis Enters Breast and Gastric Market in Brazil
Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.
Alphabet Soup: The Story Behind Biosimilar Nonproprietary Name Suffixes
Study: How Out-of-Pocket Caps Affect Payer Policy
Investigators set out to learn whether the imposition of out-of-pocket spending caps on specialty drugs would unleash a wave of drug spending and prompt payer policy change.
Revance Moves Forward With 2 Botox Competitors
With a sizable milestone payment from its partner Mylan, Revance has stepped up efforts to launch contenders in the Botox space.
The Top 5 Biosimilar Articles for the Week of August 3
Here are the top 5 biosimilar articles for the week of August 3, 2020.
CinnaGen Biosimilar Shows Promise in Treating COVID-19
A new study showed that biosimilar interferon beta-1a (IFN-β-1a) may be effective in helping to treat patients with coronavirus disease 2019 (COVID-19).
Lyman Reassures on Biosimilar Quality
Originator biologics should be monitored as closely as biosimilars, according to Gary Lyman, MD, MPH, of the Hutchinson Institute for Cancer Outcomes Research.
Samsung Bioepis Appeals to Patients Through Package Design
In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.
Anti-TNF Biologics Outperform in Crohn Disease
A real-world study on inflammatory bowel disease employing originator and biosimilar biologics suggests anti–tumor necrosis factor (TNF) therapy may be more effective for Crohn disease than for ulcerative colitis.
Teva, Alvotech Partner on Biosimilars for US Market
Teva Pharmaceutical Industries has expanded on its hopes for a biosimilar comeback with a commercialization deal with Alvotech, which could bring as many as 5 biosimilars to the US market.
Cadila Puts a Teriparatide Biosimilar on the Market
Cadila Pharmaceuticals charges ahead with yet another biosimilar launch in India, an osteoporosis agent referencing Eli Lilly's teriparatide drug Forteo.
ASCO Study: Mandatory Drug Licensing Can Bridge Care Divide
Biosimilars have improved access to health care in India, but many effective new drugs are high priced and patented, and authors of a new study recommend interventions to make these available, too.
Sizzling Growth for Republic of Korea Biopharmaceuticals Market
Biosimilar exports make up a hefty chunk of biologics and other drug exports from the Republic of Korea to the United States and Europe, according to a report.
Oubre: The Practice Perspective on Biosimilar Contracts
An oncology practice administrator describes the careful calculus involved in balancing patient needs with the business side of biosimilars and cancer care.
Alexion Offloads Market Share From Soliris
Amid the confusion of the pandemic, fundamental business strategies are reshaping the biosimilar playing field, according to corporate earnings reports.
Study: Slow Start for Infliximab Biosimilars
Investigators speculate on why infliximab biosimilars don’t have a larger market share by now.
WHO Prequalifies Second Celltrion Healthcare Biosimilar
World Health Organization (WHO) prequalification of Celltrion Healthcare’s trastuzumab opens the door for more affordable access to care for patients with breast and gastric cancers.
Biosimilars Bring Value to Health Care
Biosimilar Business Roundup: July 2020
Although the pandemic continues to affect health care companies worldwide, biosimilar manufacturers continue to move forward with new product developments and business plans.